The Global Cancer Vaccines Market is Forecast to Grow at a CAGR of 21% between 2010 and 2017

Friday 21 October 2011, Amsterdam

The Global Cancer Vaccines Market is Forecast to Grow at a CAGR of 21% between 2010 and 2017

The global cancer vaccines market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 21% between 2010 and 2017, reaching revenues of $6.3 billion in 2017 from $1.7 billion in 2010.

The cancer vaccines market was occupied by three vaccines, namely, Gardasil from Merck, Cervarix from GlaxoSmithKline (GSK), and Provenge (sipuleucel-T) from Dendreon Corporation during the historical period 2006-2010. In the near future, cervical cancer, lung cancer, pancreatic cancer and melanoma are expected to witness the launch of cancer vaccines with better efficacy over the current treatment options.
 

Promising Vaccines to be Launched in Melanoma, Lung and Pancreatic Cancer will Face Less Competition due to Absence of Marketed Vaccines

The global cancer vaccines market is presently dominated by cervical and prostate cancer vaccines. Cervical cancer is the only cancer indication to have two vaccines already available in the market and a promising vaccine in Phase III. The global cancer vaccine pipeline has a high percentage of Phase II and Phase III vaccines. The promising cancer vaccines that are first-in-class and have a novel mechanism of action will face less competition due to absence of marketed vaccines in lung cancer, pancreatic cancer and melanoma. Until 2017, cervical cancer, pancreatic cancer and melanoma are expected to have one vaccine launch each. Moreover, the pre-clinical and Phase I stages of cancer vaccine pipeline development have low percentages of vaccines. This indicates that until 2017 the global cancer vaccines market, excluding cervical and lung cancer, is not expected to face much competition until a second launch is targeted in the same indication as that of the first.


Licensing Agreements Form the Major Strategic Consolidations and North America is the Favorite Geographic Destination

The strategic consolidation landscape in the global cancer vaccines market is dominated by licensing agreements (181) followed by acquisitions (73) and co-developments (69). The major geographic concentration of strategic consolidations between 2004 and 2011 was North America, with 59% of Mergers and Acquisitions (M&A), 27% of deals and 42% of co-developments taking place in the region.

Currently, with most of the vaccines in the pipeline under various stages of development, the global cancer vaccines market is a difficult area for smaller companies to succeed in due to the high Research and Development (R&D), manufacturing and marketing costs. As a result, the vaccine companies with promising candidates in the pipeline engage in licensing agreements with financially sound companies, who in turn provide R&D, marketing, sales and regulatory support. Moreover, the vaccines market offers immense potential to generate revenues, even from smaller disease populations, for large and small companies alike. Thus, in the future, North America is expected to dominate as the major focus area for the pharmaceutical companies when it comes to M&A, licensing deals and co-development deals. One of the major reasons is expected to be their strategy to expand into newer markets. In addition, partnering with companies in different regions to market their products will enable the pharmaceutical companies to gain greater market share in those particular regions.



About this new market study:
This report provides an in-depth analysis of the five therapeutic indications for which vaccines are available in the market or which have a promising vaccine in Phase III of their pipeline. In addition, the report also includes various types of cancer vaccine development and vaccine delivery methods along with a case study, advantages and disadvantages for each type, insights into the cancer vaccines R&D pipeline, SWOT profiles of the vaccine companies, and major Mergers and Acquisitions (M&A), deals and co-developments.